NLRP3 and gestational diabetes: Recently, AS-IV has been reported to inhibit NLRP3 inflammatory body-mediated inflammation via TLR4/NF-κB/CaSR to improve vascular endothelial injury [24] and attenuate gestational diabetes mellitus via targeting NLRP3 inflammasome in diabetic mice [25].